经济观察网根据公开信息，翔丰华（300890）(300890.SZ)在近期有以下值得关注的事件： 关联交易情况 业绩经营情况 尽管公司2025年前三季度归母净利润同比下滑64.64%，但第三季度单季业绩表现亮眼，营收同比增长 31.08%，净利润同比增长26.01%。这显示出公司业绩在季度层面可能出现改善信号。 行业与风险分析 公司目前面临下游行业增速放缓、负极材料产能过剩导致的竞争加剧等挑战，产品单价和毛利率承压。 这些行业因素仍是影响公司经营的关键变量。 以上内容基于公开资料整理，不构成投资建议。 公司于2026年1月30日召开了第四届第五次董事会会议，审议了《关于公司2026年度日常关联交易预计 的议案》等文件。这表明公司已开始新一年的日常经营规划。 项目进展 根据公开资料，公司的定增募投项目，包括"6万吨人造石墨负极材料一体化生产基地建设项目"和"研发 中心建设项目"，均已延期至2026年6月。项目的后续进展对公司产能扩张和技术升级至关重要。 ...

以上内容基于公开资料整理，不构成投资建议。 经济观察网根据近期公告，迪森股份（300335）有以下值得关注的事件： 高管变动：2026年2月6日，迪森股份公告称，董事长兼总经理常远征因工作调整辞去总经理职务，副董 事长马革辞去副董事长职务，两人辞职后将继续担任公司董事及董事会相关职务。同日，公司召开第九 届第五次董事会会议，审议了《关于聘任公司总经理的议案》等文件，新总经理人选有待后续公布。 公司项目推进：2026年1月30日，迪森股份在投资者互动平台表示，淮北工厂项目已进入试生产阶段。 该项目全部完成后预计新增年产35万吨新能源车用再生低碳铝热传输材料，建设期计划为3年。 ...

Corporate Governance - The controlling shareholder of the company will change to Quantuo Zhuodai (Shanghai) Enterprise Management Center (Limited Partnership) by December 2025, with the actual controller changing to Cui Yongqing [2] - On January 16, 2026, the company completed a board restructuring, with Cui Yongqing officially elected as chairman, further optimizing the governance structure and clarifying the direction for intelligent transformation [2] Financial Performance - On January 30, 2026, the company announced a profit warning for the full year of 2025, expecting a net loss attributable to shareholders of between 70 million to 90 million yuan, primarily due to a decline in the traditional piano market, increased investment in smart product R&D, and asset impairment [3] - The financial report for the first three quarters of 2025 showed a revenue decline of 26.38% year-on-year, with a net loss attributable to shareholders of 39.85 million yuan [3] Business and Technology Development - Since 2023, the company has been advancing the intelligent transformation of its musical instrument products, launching a new AI smart digital piano series in 2025, and establishing Ningbo Quantuo Hailun Smart Technology Co., Ltd. to focus on AI software development [4] - Sales of smart musical instrument products increased by approximately 280% year-on-year, but the transformation is still in the investment phase, with R&D and marketing expenses around 16 million yuan [4] Stock and Market Performance - On February 13, 2026, the stock price closed at 14.64 yuan per share, with a single-day increase of 2.09%, but has seen a cumulative decline of 9.57% year-to-date and a 60-day decline of 17.19% [5] - The capital market has shown volatility, with a net outflow of 120,900 yuan in main funds on that day, influenced by performance and industry factors [5] Industry Policy and Environment - The company benefits from digitalization policy support in the cultural industry, such as the "14th Five-Year Plan" and capital market policies encouraging industry consolidation, but the overall industry faces challenges from shrinking traditional demand [6] - Continuous attention is needed on the effectiveness of the intelligent business implementation and progress in profit improvement [6]

经济观察网 聚石化学（股票代码：688669）近期有以下值得关注的事件，基于公开信息整理： 监管情况 针对此前的信披违规和内控问题，公司已成立专项整改小组，修订《收入确认政策》等制度，并加强内 部审计。投资者关注这些措施能否有效执行。 公司状况 公司计划聚焦主业，优化子公司布局，但液化石油气业务受国际油价波动影响显著，且精细化工项目仍 处于产能爬坡阶段，未来经营稳定性面临考验。 以上内容基于公开资料整理，不构成投资建议。 公司于2025年11月21日收到中国证监会下发的《立案告知书》，因涉嫌信息披露违法违规被立案调查。 目前调查仍在进行中，公司表示将积极配合相关工作。 业绩经营情况 公司于2026年1月29日发布2025年业绩预告，预计全年归母净利润亏损9000万元至1.2亿元，主要受液化 石油气业务亏损和精细化工项目投入期影响。正式年度报告尚未发布，后续需关注其审计结果和详细财 务数据。 公司结构与治理 ...

Group 1 - The stock price of Heshun Technology (301237) has shown volatility, with a fluctuation range of 2.06% from February 9 to 13, 2026, reaching a high of 64.80 yuan on February 11 and a low of 61.17 yuan on February 9 [1] - Daily closing prices and fluctuations are as follows: February 9 at 62.09 yuan (+0.75%), February 10 at 61.80 yuan (-0.47%), February 11 at 63.81 yuan (+3.25%), February 12 at 63.60 yuan (-0.33%), and February 13 at 62.90 yuan (-1.10%) [1] - On February 12, the net inflow of main funds was 2.1731 million yuan, and on February 13, it was 2.6997 million yuan [1] - The technical analysis indicates that the stock price is currently near the middle band of the Bollinger Bands, with a 20-day resistance level at 69.91 yuan and a support level at 59.20 yuan [1] Group 2 - For the first nine months of 2025, the company reported an operating income of 452 million yuan, representing a year-on-year growth of 23.53%, but the net profit attributable to shareholders was -22.9551 million yuan, a slight decrease of 2.27% year-on-year [2] - The main business revenue composition is primarily from non-ferrous optoelectronic base films (45.46%) and transparent films (42.62%) [2] - Despite revenue growth, the company remains in a loss position, indicating cost pressures or competitive impacts within the industry [2] Group 3 - Institutions have a generally optimistic outlook on Heshun Technology's future profitability, with four institutions predicting a net profit attributable to shareholders of 15 million yuan for 2025, a year-on-year increase of 131.82%, and a forecast of 39 million yuan for 2026, reflecting a growth rate of 160.00% [3] - Overall public sentiment is neutral, with the company ranking high in industry research frequency (8 out of 439), but there is currently no clear target price forecast [3]

以上内容基于公开资料整理，不构成投资建议。 经济观察网根据近期公告，银邦股份（300337）值得关注的事件是公司于2026年2月3日收到HOLTEC ASIA PRIVATE LIMITED的销售订单，预计金额约2.8亿元(不含税)，履行期限为2026年1月1日至2027年 12月31日。该订单涉及铝钢复合材料和铝铝复合材料供应，预计将对公司2026年及2027年的营业收入和 营业利润产生积极影响。 ...

Group 1 - The core viewpoint of the article highlights that Dazhong Laser (002008) has secured multiple significant projects in the display panel industry, indicating strong recognition of its technological capabilities by major clients like BOE and TCL Huaxing [1] - The demand for AI-driven high multilayer PCB equipment, semiconductor, and display panel equipment is showing signs of recovery [1] Group 2 - In terms of financial performance, the company's revenue for the first three quarters of 2025 increased by 25.51% year-on-year, while the net profit attributable to shareholders decreased by 39.46%, primarily due to non-recurring gains and losses; however, the net profit excluding non-recurring items grew by 51.46%, indicating improved profitability in core operations [2] Group 3 - As of February 13, 2026, the company's stock price closed at 54.50 yuan, showing a recent upward trend with a daily increase of 2.62% and a 5-day increase of 13.42% [3] Group 4 - From a technical perspective, as of February 13, 2026, the stock price has surpassed the 20-day moving average of 50.16 yuan, with the 60-day moving average at 43.08 yuan; the current price is near the upper Bollinger Band of 54.29 yuan, indicating a need to monitor volume and previous resistance levels [4] Group 5 - Institutional target prices average around 71.40 yuan, although market sentiment and macroeconomic fluctuations may impact stock prices [5]

Industry Overview - The semiconductor equipment sector has shown strong performance recently, with the semiconductor equipment concept index rising by 1.85% on February 13, making it one of the few sectors to gain that day [1] - According to the Semiconductor Industry Association, global semiconductor sales are projected to reach $791.7 billion by 2025, a year-on-year increase of 25.6%, with sales in China exceeding $200 billion for the first time, growing over 15% [1] - TSMC reported a year-on-year sales increase of 36.8% to NT$401.26 billion in January, and its capital expenditure plan for 2026 (ranging from $52 billion to $56 billion) indicates strong demand for upstream equipment [1] - Factors such as AI computing demand, an upturn in the storage chip cycle, and the penetration of advanced packaging technology are driving equipment demand [1] Company Fundamentals - Jingyi Equipment's revenue for Q3 2025 increased by 37.96% year-on-year to 368 million yuan, with a cumulative revenue growth of 42.81% for the first three quarters [2] - As of the end of Q3 2025, the company's contract liabilities reached 951 million yuan, and inventory increased by 190 million yuan to 2.349 billion yuan, indicating a robust order intake and significant delivery pressure [2] - The company's products are utilized in major domestic wafer fabs such as Yangtze Memory Technologies and SMIC, holding approximately 39% market share in the domestic semiconductor temperature control equipment sector (2024 data) [2] Financial Situation - On February 13, Jingyi Equipment experienced a net outflow of 45.377 million yuan in main funds, but the daily trading volume reached 1.087 billion yuan, with a turnover rate of 7.20%, indicating significant capital divergence [3] - The stock price exhibited considerable volatility on that day, with a high of 128.75 yuan and a low of 117.18 yuan, likely influenced by pre-holiday risk aversion and profit-taking [3] Stock Price Situation - February 13 marked the last trading day before the Lunar New Year, with the A-share market experiencing a general decline (Shanghai Composite Index down 1.26%), as funds shifted from high-position sectors like photovoltaics and small metals to defensive sectors such as semiconductor equipment and military [4] - As a leading player in the semiconductor equipment niche, Jingyi Equipment benefits from the strengthening of domestic substitution logic, with a year-to-date increase of 26.64%, indicating a potential short-term rebound due to technical factors [4] - The recent stock price fluctuations of Jingyi Equipment are attributed to multiple factors, including improved industry sentiment, robust company orders, capital market dynamics, and shifts in market style [4]

经济观察网据国家市场监督管理总局网站2月12日晚消息，针对近期雀巢婴配乳粉因检出蜡样芽胞杆菌呕吐毒素预防性召回事件，国务院食安 办、市场监管总局高度重视，已督促雀巢(中国)有限公司完成其在中国大陆销售的特定批次产品召回工作。 截至目前，我国未发现因食用婴幼儿配方乳粉导致蜡样芽胞杆菌呕吐毒素中毒的确诊病例。 市场监管总局已部署各地强化婴幼儿配方乳粉质量安全管控，督促所有生产企业开展蜡样芽胞杆菌呕吐毒素检测，严格原料验收和产品出厂把 关，全力保障婴幼儿配方乳粉质量安全。 ...

经济观察网基于最新公开信息，诺诚健华-U(688428)在2026年有以下值得关注的事件进展，主要涉及临 床研发、合作推进和产品商业化等方面。 临床研发进展 ICP-488(高选择性TYK2抑制剂)：2026年2月2日，公司宣布其治疗银屑病的III期临床试验已完成患者入 组，共入组383例患者，标志该药取得关键临床节点。 Soficitinib(TYK2抑制剂)：2026年年初，治疗中重度特应性皮炎的III期注册临床试验已完成患者入组； 该药治疗白癜风、结节性痒疹等适应症的临床试验也在加速推进。 奥布替尼(BTK抑制剂)： 可持续盈利基础：公司2025年首次实现扭亏为盈(营收约23.7亿元，归母净利润约6.3亿元)，管理层表示 将从2025年起进入可持续盈利阶段，重点通过全球化布局和管线多元化巩固业绩。 以上内容基于公开资料整理，不构成投资建议。 治疗特发性血小板减少性紫癜(ITP)的III期临床研究已完成，预计2026年上半年提交新药上市申请 (NDA)。 治疗系统性红斑狼疮(SLE)的IIb期研究已达到主要终点，III期注册临床试验即将启动。 BCL2抑制剂(Mesutoclax/ICP-248)：目前正 ...